|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Super pH-sensitive multifunctional polymeric micelle for tumor pH(e) specific TAT exposure and multidrug resistance.
|
18539355 |
2008 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
CPP2 could more selectively penetrate CRC cells than TAT or R8 as well as effectively deliver the p16MIS to the tumor.
|
27485348 |
2016 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
We have previously shown that a cell-permeable peptide derived from the p120 Ras GTPase-activating protein (RasGAP), called TAT-RasGAP317-326, bears anti-malignant activities in vitro and in vivo, such as inhibition of metastatic progression and tumor cell sensitization to cell death induced by various anti-cancer treatments.
|
27602963 |
2016 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
DC/CRT-TAT-DeltaCEA had the additional effects of CRT and TAT PTD and enhanced the anti-tumor effect against CEA-expressing tumors compared to DC/CRT-DeltaCEA or DC/TAT-DeltaCEA.
|
18812201 |
2008 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Following administration, <sup>D</sup> TRCD experiences prolonged circulation by masking the targeting effect of its TAT peptide and then achieves enhanced tumor cell uptake and improved translocation into the perinuclear region by reactivating the TAT targeting capability in tumor tissue.
|
31318147 |
2019 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Glial tumors probably arise from a complex interplay of factors; possibilities include the activation of a dominant oncogene or viral inactivation of a tumor suppressor gene by a viral promoter (like the tat protein), impairment of immune defenses (which facilitates the growth of astrocytomas in acute lymphoblastic leukemia), production of cellular growth factors, cytokines, possible infection of glial cells by HIV, and the potentiation of a coinfectious agent.
|
8033048 |
1994 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
It was further passivated by thiolated poly(ethylene glycol)-tumor homing peptides (NGR and TAT) to improve its cancer tissue penetrating, and accurate targeting ability.
|
31847931 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Importantly, when fused to the tat protein-transduction sequence and subsequently introduced into cells, the C2 peptides potently promoted the RhoGAP function in DLC1, leading to decreased RhoA activation and reduced tumor cell growth in soft agar and migration in response to growth factor stimulation.
|
31806702 |
2020 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Herein, a polymeric nanoparticle with tumor acidity (pH<sub>e</sub>)-activatable TAT targeting ligand that encapsulates the photosensitizer chlorin e6 (Ce6) and chelates contrast agent Gd<sup>3+</sup> is successfully developed for fluorescence/magnetic resonance (MR) dual-model imaging-guided precision PDT.
|
28437627 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
HIV1-TAT interactive protein (TIP60) is a haploinsufficient tumor suppressor.
|
29045464 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The co-administration of iRGD strengthened the permeability of kla-TAT peptide against A549 2D and 3D sphere model with the penetration improvement property of iRGD; more importantly, co-administration with iRGD dramatically enhanced the accumulation of kla-TAT peptide in tumor tissue on the xenograft mice model with the homing property of iRGD.
|
29722179 |
2018 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Human KS SLK cells were injected subcutaneously into CD4(+) T-cell-depleted male mice, and the tumors that formed after 3-4 weeks were recovered and analyzed for the expression of Tat protein(s), different cytokine messenger RNAs (mRNAs), and matrix metalloproteinases (MMPs).All statistical tests were two-sided.
|
10793108 |
2000 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Moreover, while tumor cell infectivity was severely reduced for Ad5 in the presence of fiber proteins, it was only marginally reduced for Tat-PTD-modified Ad5.
|
21957304 |
2011 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
This TAT-vault nanoparticle could be a valuable tool for improving the retention and penetration of therapeutic drugs at tumor sites.
|
22785558 |
2013 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Combining the cell-internalizing property of TAT with the tumor-specific property of tumstatin7 may provide a useful adjunct to tumor therapy.
|
30522555 |
2018 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Instead of vascular tumors, the tat gene of HTLV-I causes thymic atrophy and mesenchymal tumors in transgenic mice.
|
1657029 |
1991 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The tat gene of HTLV-1 under control of its own long terminal repeat is capable of inducing tumors in transgenic mice.
|
2888191 |
1987 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The targeted inhibition of Livin by the cell-permeable peptide (TAT-Lp15) in intracerebral glioblastoma-bearing mice demonstrated a synergistic suppression of tumor growth and increased the survival rate in standard-of-care treatment with radiation plus temozolomide.
|
25370472 |
2015 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The folic acid and TAT peptide dual-ligand liposome also demonstrated enhanced tumor penetration as observed using 3D tumor spheroid models.
|
29908938 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Next, to investigate tumor growth delay after irradiation, HCT116 cell lines were selected and xenografted onto nude mice that were then treated with TAT-RasGAP<sub>317-326</sub> alone or in combination with radiation or cisplatin.
|
28323576 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Treatment of tumor cells expressing the CXCR4 receptor with either the DV3-TATp53C' or DV3-TAT-RxL targeted peptides resulted in an enhancement of tumor cell killing compared with treatment with nontargeted parental peptides.
|
16322205 |
2005 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
These include the angiogenesis of the tumour and the possible role of growth factors, such as the HIV-transactivating (tat) gene product and interleukin-6, the possible meaning of immunomodulating activities of interferon-alpha, such as the rise in the number of CD4+ cells and the increase in beta 2-microglobulin serum concentrations in patients whose tumours respond to treatment, and the observed association between interferon's antiretroviral activity and tumour responses.
|
1588254 |
1992 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Here, we report that TAT-RasGAP(317-326) requires p53, but not the Ras effectors Akt and extracellular signal-regulated kinase, to mediate its tumor sensitization abilities.
|
17510315 |
2007 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Introduction of the TAT gene into HCC cell lines could effectively inhibit colony formation in soft agar, foci formation, and tumor formation in nude mice.
|
20209601 |
2010 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Our results suggest that TAT-mediated transduction may be a useful strategy for the therapeutic delivery of large tumor suppressor molecules to malignant cells in vivo.
|
14966535 |
2004 |